Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

Core Insights - Xenon Pharmaceuticals presented three posters at the 15th European Epilepsy Congress, showcasing long-term data and improved quality of life outcomes for adults with focal onset seizures treated with azetukalner, a novel Kv7 channel opener [1][2] Company Overview - Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to developing therapeutics for neurological and psychiatric disorders, with a focus on high unmet medical needs such as epilepsy and depression [4] Clinical Data - Azetukalner is the only Kv7 potassium channel opener in clinical development supported by Phase 2b data, demonstrating over 90% reduction in median monthly seizure frequency for patients in the open-label extension study [2][5] - Approximately 25% of patients on azetukalner for at least two years experienced a year or longer of seizure freedom [2] Presentations at EEC - Poster P282: Interim data from the ongoing X-TOLE study in adults with focal onset seizures [3] - Poster P281: Improvements in quality of life for adults with focal onset seizures treated with azetukalner [3] - Poster P406: Non-seizure symptoms, mental health comorbidities, and quality of life in patients with focal onset seizures [3] Ongoing Clinical Trials - Xenon's Phase 3 epilepsy program includes three ongoing trials for focal onset seizures and primary generalized tonic-clonic seizures, evaluating the efficacy and safety of azetukalner [5]